Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: A pooled analysis of 3-year phase III trials

British Journal of Ophthalmology

Volumn 100, Issue 6, 2016, Pages 796-801

  Danis, Ronald P ^a   Sadda, Srinivas ^b   Li, Xiao Yan ^c   Cui, Harry ^c   Hashad, Yehia ^c   Whitcup, Scott M ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b DOHENY EYE INSTITUTE   (United States)

^c ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESOXIMETASONE; DEXAMETHASONE; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA FLUORESCEIN ANGIOGRAPHY; VISUAL ACUITY; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DIAGNOSTIC IMAGING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG IMPLANT; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; OPTICAL COHERENCE TOMOGRAPHY; RETINA; TIME FACTOR; TREATMENT OUTCOME; VITREOUS BODY;

DEXAMETHASONE; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG IMPLANTS; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RETINA; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 84965058183     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-306823     Document Type: Article

References (22)

1. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res 2013;34:19-48.
2. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008;30:65-84.
3. Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
4. Ehrlich R, Harris A, Ciulla TA, et al. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 2010;88:279-91.
5. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011;30:343-58.
6. Boyer DS, Hopkins JJ, Sorof J, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4:151-69.
7. Song SJ, Wong TY. Current concepts in diabetic retinopathy. Diabetes Metab J 2014;38:416-25.
8. Bandello F, Cunha-Vaz J, Chong NV, et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye 2012;26:485-93.
9. Kim YH, Choi MY, Kim YS, et al. Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage. Life Sci 2007;81:1167-73.
10. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-4.
11. Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013;7:1423-8.
12. Callanan DG, Gupta S, Boyer DS, et al., for the Ozurdex PLACID Study Group. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120:1843-51.
13. Boyer DS, Yoon YH, Belfort R Jr, et al., for the Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-14.
14. [No authors listed]. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(Suppl 5):786-806.
15. [No authors listed]. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(Suppl 5):807-22.
16. Boyer DS, Faber D, Gupta S, et al., for the Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-23.
17. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96.
18. Kozak I, Morrison VL, Clark TM, et al. Discrepancy between fluorescein angiography and optical coherence tomography in detection of macular disease. Retina 2008;28:538-44.
19. Otani T, Kishi S. Correlation between optical coherence tomography and fluorescein angiography findings in diabetic macular edema. Ophthalmology 2007;114:104-7.
20. Stratton IM, Kohner EM, Aldington SJ, et al., for the UKPDS Group. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-63.
21. Leung CK, Cheung CY, Weinreb RN, et al. Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 2008;49:4893-7.
22. Frank RN, Schulz L, Abe K, et al. Temporal variation in diabetic macular edema measured by optical coherence tomography. Ophthalmology 2004;111:211-17.